MT1A and diabetes mellitus: In vivo, intraperitoneal injection of Tat-MT1A in mice showed possible delivery into islets, and mice receiving 8 injections of Tat-MT1A over 11 days were partially protected against diabetes induced by multiple low doses of STZ.